Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (586)	7/1/2004 12:54:59 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

VICL The stock has found support this month at the 5.30 level. On May 13 it traded as low as 4.55,and it needs now to close above the June 4 H of 6.23 (Today was the 3rd day up on a roll.<g>) VICL has around $4 in cash/share.EE for 2004 are still on the red column (loss of $1.35/share.) The PII of high-dose Allovectin in patients with metastatic melanoma showed an overall response rate of 10.2%, with two complete responders and 11 partial responders. Except for last year when the H in July was $7.80 VICL since 1997 has always traded above the $12 level some time within its fiscal year.<g> bigcharts.marketwatch.com bigcharts.marketwatch.com Bernard